Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal Science

Executive Summary: Moxidectin is a macrocyclic lactone anthelmintic with FDA-approved indications for parasitic worm control in animals and humans (source: product_spec). Its mechanism involves binding glutamate-gated chloride channels in nematodes. Recent research shows moxidectin activates ergosterol biosynthesis in Candida albicans, synergizing with polyene antifungals to suppress oral candidiasis (source: paper). The compound offers persistent antiparasitic efficacy (12–16 weeks post-dose in horses) and high water/organic solubility (source: product_spec). Supplied by APExBIO (SKU B3611), moxidectin is characterized by high purity and robust QC data.

Biological Rationale

Moxidectin addresses the growing challenge of parasitic worm control in veterinary and human health. In horses, it targets Strongylus vulgaris and reduces fecal egg count for up to 16 weeks post-treatment (source: product_spec). In cattle, it is effective against Ostertagia ostertagi. Its recent repurposing in fungal disease is motivated by the rising incidence and resistance in Candida albicans infections, especially among immunocompromised and elderly patients. The World Health Organization lists C. albicans among critical fungal pathogens (source: paper).

Mechanism of Action of Moxidectin

Moxidectin exerts its anthelmintic effects by binding to glutamate-gated chloride channels in the nervous system of nematodes, leading to hyperpolarization, paralysis, and death of the parasite (source: product_spec). In fungal systems, moxidectin triggers the transcriptional upregulation of ergosterol biosynthesis in Candida albicans, which enhances the binding and efficacy of polyene antifungals such as amphotericin B and nystatin (source: paper). This mechanistic synergy is confirmed by loss of effect in ergosterol-pathway mutants (Δ/Δerg3, Δ/Δerg11).

Evidence & Benchmarks

• Moxidectin maintains persistent antiparasitic efficacy, reducing fecal egg counts for 12–16 weeks post-administration in horses at 0.4 mg/kg (source: product_spec).
• FDA approved moxidectin in 2018 for onchocerciasis (river blindness) in humans, indicating translational safety (source: FDA).
• In vitro, moxidectin activates C. albicans ergosterol biosynthesis, restoring polyene sensitivity in 60 clinical isolates (source: paper).
• Combination of moxidectin with amphotericin B or nystatin reduces C. albicans infection area and tongue inflammation in a murine model of oral candidiasis (source: paper).
• Moxidectin is highly soluble (≥128 mg/mL in ethanol, ≥129.4 mg/mL in DMSO, ≥3.27 mg/mL in water with warming/ultrasonication), supporting assay versatility (source: product_spec).

Applications, Limits & Misconceptions

Moxidectin’s core veterinary value is in nematode control for horses, cattle, cats, and dogs. Its human application is currently limited to onchocerciasis. In mycology, its utility lies in potentiating polyene antifungals for C. albicans when resistance or side effects limit standard therapies (source: paper). Misconceptions include assuming efficacy for all fungal species or all parasitic infections, or its suitability as a monotherapy for fungal disease. Moxidectin’s antifungal utility is dependent on the presence of intact ergosterol biosynthesis pathways in the pathogen.

Common Pitfalls or Misconceptions

• Moxidectin does not exhibit antifungal activity as monotherapy against ergosterol-pathway-deficient C. albicans mutants (paper).
• It is not a replacement for azole antifungals or echinocandins in non-Candida applications (workflow_recommendation).
• Veterinary dosing regimens should not be extrapolated to human or laboratory fungal models without validation (product_spec).
• Long-term storage of moxidectin solutions is not recommended due to stability concerns (source: product_spec).
• Polyene synergy is unlikely in pathogens that lack ergosterol or its synthesis machinery (source: paper).

Workflow Integration & Parameters

APExBIO supplies high-purity moxidectin (SKU B3611), with full QC data (HPLC, NMR) and a recommended storage temperature of -20°C. For optimal solubility, dissolve at ≥128 mg/mL in ethanol or ≥129.4 mg/mL in DMSO, or ≥3.27 mg/mL in water with gentle warming and ultrasonication (source: product_spec). Solutions should be freshly prepared for critical assays. In animal models, such as Shetland horses, 0.4 mg/kg is administered as an oral paste (source: product_spec).

Protocol Parameters

• in vivo antiparasitic efficacy | 0.4 mg/kg (paste, oral, horse) | veterinary nematode control | Established for Strongylus vulgaris; persistent effect | product_spec
• antifungal synergy assay | 4–16 µg/mL (in vitro, C. albicans) | polyene potentiation | Elevates ergosterol, enhances AmB/nystatin activity | paper
• solubility for assay prep | ≥128 mg/mL (ethanol), ≥129.4 mg/mL (DMSO), ≥3.27 mg/mL (water, warmed/sonicated) | laboratory workflows | Ensures high-concentration stock prep | product_spec
• storage | -20°C (dry powder) | all domains | Maintains stability and QC | product_spec
• solution stability | Use freshly prepared | all domains | Prevents compound degradation | workflow_recommendation

For detailed assay troubleshooting and cross-domain protocol guidance, see Moxidectin (SKU B3611): Optimizing Antifungal Assays in the Lab (this article discusses practical workflow solutions not covered here), and Moxidectin: Macrocyclic Lactone Anthelmintic for Antifungal Synergy (for hands-on protocol optimization in synergy testing). This article extends these by integrating latest mechanistic and benchmark data from 2024 peer-reviewed research.

Conclusion & Outlook

Moxidectin, long established for veterinary antiparasitic use, now demonstrates validated synergy with polyene antifungals against C. albicans via ergosterol pathway activation. Its high solubility and robust QC make it suitable for translational antifungal workflows. While promising as a polyene potentiator in oral candidiasis models, its application is limited by the ergosterol dependence of the effect and by regulatory domain boundaries. Future directions involve further clinical validation of this synergy and expanded mechanistic study in other fungal pathogens, as outlined in the current literature (source: paper).

For ordering or further specifications, see the APExBIO Moxidectin product page.